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ietary intake of fish oil and serum levels of omega-3 polyunsaturated fatty acids (n-3 PUFAs) have been shown to be inversely correlated with cardiovascular morbidity and mortality of coronary artery disease (CAD) in many epidemiological studies. 1, 2) (n-3) PUFAs have suppressive effects on the initiation and progression of atherosclerosis mainly through their antiinflammatory properties. 3) At the initiation of atherosclerosis, injured endothelium expresses adhesion molecules and produces cytokines, growth factors and vasoactive molecules, leading to the infiltration of monocytes and T lymphocytes into the sub-endothelial space. 4) These inflammatory cells release enzymes, cytokines, chemokines, eicosanoids, and growth factors followed by chronic inflammation within the vascular wall. In this way, inflammation plays pivotal roles in the onset and/or progression of atherosclerotic diseases. Under stimulation, arachidonic acid (AA) is released from membrane phospholipids of inflammatory cells and metabolized by cyclooxygenase (COX) or lipoxygenase (LOX) to produce pro-inflammatory eicosanoids, such as prostaglandin E2 and leukotriene B4. On the other hand, n-3 PUFAs prevent the conversion of AA into proinflammatory eicosanoids by serving as an alternative substrate for COX or LOX, resulting in the production of biologically weaker pro-inflammatory eicosanoids, such as prostaglandin E3 and leukotriene B5 (Figure) . 5) In addition, resolvin, protectin, and maresin, which are derived from eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA) via COX and LOX pathways, were shown to have anti-inflammatory properties in cell culture and animal studies.
6,7) Also, EPA and DHA can directly decrease adhesion molecule expression on the surface of monocytes, macrophages, or endothelial cells. 8, 9) In humans consuming typical Western diets, the membrane phospholipids of inflammatory cells are rich in AA, which is an n-6 PUFA, and poor in EPA and DHA, which are n-3 PUFAs. [10] [11] [12] The content of n-3 PUFAs in inflammatory cells was reported to be augmented by the increased intakes of EPA and DHA. [10] [11] [12] Thus, dietary intake of fish oil or supplementation of n-3 PUFAs are thought to play antiinflammatory and anti-atherosclerotic roles by altering the fatty acid composition in inflammatory cells.
At the advanced stage of atherosclerosis, these inflammatory cells secrete matrix metalloproteinases (MMPs) and cysteine proteases which could thin and weaken the fibrous cap, making the plaque vulnerable. 13) A randomized placebo-controlled trial in patients who underwent carotid endarterectomy 14) showed that n-3 PUFAs are incorporated into advanced atherosclerotic plaques after dietary supplementation of both EPA and DHA, followed by a reduced number of macrophages infiltrating into the plaques, suggesting n-3 PUFAs have a plaquestabilizing effect. Also, the follow-up study OCEAN (Omacor Carotid EndArterectomy iNtervention) reported that mRNA levels of MMP-7, MMP-9 and MMP-12 were lower in carotid plaques in patients who had received EPA and DHA supplementation. 15) Serum EPA levels are significantly lower in patients with acute coronary syndrome (ACS) than in patients with stable angina, and serum DHA levels are also low in ACS patients, [16] [17] [18] [19] [20] [21] which is consistent with the findings that the coronary atherosclerotic plaques in ACS patients, even if they are non-culprit lesions, are more vulnerable than those in patients with stable angina. 22) Also, in non-ACS patients, a lower serum content of n-3 PUFA was significantly associated with lipid-rich plaques. 19) 
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In a cross-sectional study, Shimada, et al. 23) first reported that low serum EPA levels were independent risk factors for multiple vessel disease in patients with ST elevation myocardial infarction (STEMI). A total of 507 STEMI patients who had undergone emergency percutaneous coronary intervention were classified into 3 groups; one-vessel disease, two-vessel disease, and three-vessel disease/left main trunk disease. In this study, the relationship between serum PUFAs and extent of vessel disease was evaluated without distinction between culprit and Nakao, ET AL
Figure.
Mechanisms for anti-inflammatory properties of n-3 PUFAs. 1) (n-3) PUFAs prevent the conversion of arachidonic acid into pro-inflammatory eicosanoids. 2) (n-3) PUFAs serve as an alternative substrate for cyclooxygenase or lipoxygenase, resulting in the production of biologically weaker pro-inflammatory eicosanoids. non-culprit lesions. Recent investigations using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) demonstrated that low serum levels of n-3 PUFAs were associated with lipid-rich plaque in culprit lesions for stable angina. 19, 24) The association of low serum levels of n-3 PUFAs and vulnerable plaques in non-culprit lesions detected by IVUS in patients with stable angina who had undergone at least 8 months of lipid-lowering therapy with a statin was also reported. 25) Consistent with these findings in non-ACS patients, the inverse association between serum n-3 PUFA levels and extent of vessel disease identified in Shimada's study might imply an inverse correlation of serum n-3 PUFA levels and the amount of vulnerable coronary atherosclerotic plaques, whether culprit or non-culprit.
As a gold standard to explore the vulnerability of coronary atherosclerotic plaques, invasive imaging modalities, such as IVUS, OCT, coronary angioscopy, and coronary computed tomography are currently performed. Using IVUS and OCT, culprit plaques for ACS were shown to have a thinner fibrous cap as compared with non-culprit plaques. 22) In ACS patients, a non-culprit plaque is likely to become the culprit lesion for the near term recurrence of ACS. Further studies are needed to clarify the association between the serum levels of PUFAs and vulnerability of coronary atherosclerotic plaques in ACS patients with distinction between culprit and non-culprit lesions, enabling us to verify the clinical usefulness of serum n-3 PUFAs levels as a reliable and non-invasive marker for vulnerable plaques in coronary arteries.
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